Clinical trials are a necessary part of the research required to evaluate the impact of interventions, such as drugs and devices, on health. However, most clinical trials fail to adequately enroll individuals from racially and ethnically diverse backgrounds. This report describes work that Eli Lilly and Company (Lilly) and The Network for Excellence in Health Innovation (NEHI) completed together to improve diverse participation in clinical trials and advance health equity. From 2022 through 2024, Lilly and NEHI (the Core Team) convened leaders from organizations in Indiana that shared this goal. This group identified barriers to clinical trial participation from a range of perspectives, identified ways to overcome those barriers, and implemented a solution to an issue they prioritized (the need to provide additional knowledge and awareness about clinical trials to diverse communities in Indiana through messengers that those communities trust).
.png?width=75&height=75&name=Download%20(5).png)
Co-Authors:
